Method for culture of cells
US-2021002608-A1 · Jan 7, 2021 · US
Method for producing enteric neural precursors
US12516288B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12516288-B2 |
| Application number | US-201917270162-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 21, 2019 |
| Priority date | Aug 22, 2018 |
| Publication date | Jan 6, 2026 |
| Grant date | Jan 6, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A method for producing enteric neural precursors, comprising the steps of: (1) providing enteric neural precursors; and (2) culturing the enteric neural precursors in a medium comprising an ERBB3 agonist and/or an ERBB4 agonist is provided as a technique for allowing enteric neural precursors to proliferate by culture while maintaining their differentiation capacity into enteric nerve cells and glial cells.
First claim
Opening claim text (preview).
The invention claimed is: 1 . A method for producing enteric neural precursor cells, comprising the steps of: (1) providing SOX10-positive and PHOX2B-negative neural crest cells; (2) culturing the neural crest cells for differentiation in a medium comprising NRG1 and retinoic acid and/or a derivative thereof, thereby producing enteric neural precursor cells, wherein the derivative of retinoic acid is one or more selected form the group consisting of retinol, retinal, retinoin, isoretinoin, alitretinoin, etretinate, acitretin, tazarotene, bexarotene, and adapalene, wherein the medium comprises a TGFβ inhibitor and GSK3β inhibitor, wherein the enteric neural precursor cells are SOX10-positive and PHOX2B-positive; and (3) culturing the enteric neural precursor cells for proliferation, for a period of at least 40 days, in a medium comprising NRG1 and retinoic acid and/or derivative thereof, wherein the expanded enteric neural precursor cells are SOX10-positive and PHOX2B-positive. 2 . The production method according to claim 1 , wherein the neural crest cells of step 1 are vagal neural crest cells. 3 . The production method according to claim 1 , wherein the neural crest cells of step 1 are HOXB5-positive and HOXB9-negative. 4 . An expansion culture method for enteric neural precursor cells, comprising the steps of: (1) providing SOX10-positive and PHOX2B-positive enteric neural precursor cells; and (2) culturing the enteric neural precursor cells for proliferation, for a period of at least 40 days, in a medium comprising NRG1 and retinoic acid and/or derivative thereof, thereby expanding enteric neural precursor cells, wherein the derivative of retinoic acid is one or more selected form the group consisting of retinol, retinal, retinoin, isoretinoin, alitretinoin, etretinate, acitretin, tazarotene, bexarotene, and adapalene, wherein the medium comprises a TGFβ inhibitor and GSK3β inhibitor, wherein the expanded enteric neural precursor cells are SOX10-positive and PHOX2B-positive. 5 . The production method according to claim 1 , wherein the medium of step (2) or (3) further comprises a glial cell-derived neurotrophic factor (GDNF). 6 . The production method according to claim 1 , wherein the medium of step (2) or (3) further comprises a soluble basement membrane preparation extracted from Engelbreth-Holm-Swarm (EHS) mouse sarcoma. 7 . The production method according to claim 1 , wherein the medium of step (2) or (3) comprises NRG1 at a concentration of 50 to 200 ng/ml. 8 . The method according to claim 4 , wherein the medium further comprises a glial cell-derived neurotrophic factor (GDNF). 9 . The method according to claim 4 , wherein the medium further comprises a soluble basement membrane preparation extracted from Engelbreth-Holm-Swarm (EHS) mouse sarcoma. 10 . The method according to claim 4 , wherein the medium comprises NRG1 at a concentration of 50 to 200 ng/ml.
Assignees
Inventors
Classifications
Small molecules not provided for elsewhere · CPC title
Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins · CPC title
Organic components · CPC title
Stomach, intestines · CPC title
for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12516288B2 cover?
- A method for producing enteric neural precursors, comprising the steps of: (1) providing enteric neural precursors; and (2) culturing the enteric neural precursors in a medium comprising an ERBB3 agonist and/or an ERBB4 agonist is provided as a technique for allowing enteric neural precursors to proliferate by culture while maintaining their differentiation capacity into enteric nerve cells and…
- Who is the assignee on this patent?
- Univ Kyoto, Takeda Pharmaceuticals Co
- What technology area does this patent fall under?
- Primary CPC classification A61L27/3882. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 06 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).